Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics.

Jessie R SignorelliThuy TranMarie E SirekYarelis Díaz-RohenaJodi L TarabaBenyam MulunehNayanika BasuJennifer LillyJulianne Darling

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

The creation of a tool to predict nonadherence prior to starting therapy is an unmet need for patients initiating oral oncolytics. The aim of this tool is to meet those needs and better guide clinicians to provide patients with strategies to better manage nonadherence. Next steps include tool validation and piloting in clinical practice.

Keyphrases

risk assessment
end stage renal disease
clinical practice
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
palliative care
stem cells
human health
patient reported outcomes